Scienture signs exclusive REZENOPY distribution deal covering 2,000 U.S. addiction clinics
AI Summary- Scienture signed an exclusive agreement to distribute REZENOPY through U.S. addiction treatment networks.
- IQVIA recorded approximately $140 million in U.S. naloxone sales across 9.8 million units.
- REZENOPY received FDA approval on April 19, 2024, before Scienture secured rights in March 2025.